Consortium of Eosinophilic Gastrointestinal Disease Researchers

描述（由申请人提供）：本申请旨在促进嗜酸性粒细胞食管炎（EoE），嗜酸性粒细胞胃炎（EG）和嗜酸性粒细胞结肠炎（EC）的研究，通过发展嗜酸性粒细胞胃肠道疾病研究人员联盟（CEGIR）。CEGIR包括俄亥俄州（协调中心）、科罗拉多州、加利福尼亚州、印第安纳州、宾夕法尼亚州、伊利诺伊州、北卡罗来纳州、马萨诸塞州、瑞士和马里兰州的临床中心。所有参与的国内，非国家卫生研究院（NIH）临床中心都与临床转化科学奖（CTSA）相关。CEGIR的场址是根据它们彼此以前的合作记录精心选择的；多样化的

DESCRIPTION (provided by applicant): This application aims to facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR comprises clinical centers in Ohio (the coordinating center), Colorado, California, Indiana, Pennsylvania, Illinois, North Carolina, Massachusetts, Switzerland, and Maryland. All participating domestic, non-National Institutes of Health (NIH) clinical centers are associated with a Clinical Translational Science Award (CTSA). The CEGIR sites have been carefully chosen on the basis of their preexisting record of collaboration with each other; diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, and Pathology; the ability to integrate pediatric and adult patients into a common consortium; and well-established record of excellence in clinical research involving this patient population. Importantly, the CEGIR sites have proven access to an adequate number of patients with the rare diseases studied, as evidenced from the recent completion of the first set of controlled clinical trials involving this patient population. Strong patient advocacy groups (PAGs), including the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED), already partner with the CEGIR Investigators and will continue to work synergistically in the context of CEGIR. Despite the recent record of advances by CEGIR Investigators, the early success of their collaborative interactions, the proactive PAGs, and the development of novel anti-eosinophil therapeutics, there is no currently existing funding for a clinical network focusing on these three rare, distinct diseases, highlightig the timeliness and importance of this application.